Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Not applicable

The Effect of Animation-Based Education on Menopausal Women's Attitudes, Behaviors, and Screening Test Participation Regarding Breast Cancer

NCT07042737 · tracked via the Priya Life Science Turkey tracker
Phase
Not applicable
Started
2025-06-20
Last updated
2025-06-29

Condition(s) studied

Menopausal WomenEducation NursingBreast Cancer FemalesMotivationScreening Strategy

Investigational drug(s) / intervention(s)

animation-based breast cancer educationControl group (placebo)

animation-based breast cancer education: The animation-based humorous application consists of four videos, each lasting 40-45 minutes, which separately explain the signs and symptoms of breast cancer, self-breast examination, clinical breast examination, and mammography through animation.

Control group (placebo): No intervention will be applied to the control group.

Study summary

The aim of this study was to determine the effect of education provided to women in menopause through animation on their attitudes toward breast cancer, behaviors, and screening test participation. The study will include a total of 136 women in the menopausal period, comprising 68 experimental group participants and 68 control group participants who have applied to the Orduyeri and Kırtepe Family Health Centers affiliated with the Bartın Public Health Institution. Women who agree to participate in the project, which will run from January to August 2025, will receive 40-45 minute training sessions in a suitable room at the ASM. The training sessions will be conducted in groups of 8-12 people. The training content will include information about the purpose, duration, and rules of the training. After providing information about the project, a pre-test will be administered. Through face-to-face interviews, researchers assigned to the project will show animated videos enriched with sound and images via an online program they have prepared. These videos will be 10-12 minutes long, and an interim test will be conducted. Three months after the pre-test, the women participating in the study will be contacted, and a final test will be administered in their own homes. Project data will be collected using the Personal Information Form, Champion Health Belief Scale, and Breast Cancer Awareness Scale. Descriptive statistics, independent sample t-tests, chi-square tests, and repeated measures analysis of variance (ANOVA) tests will be used in the statistical analysis of the project.

Eligibility

Sex
FEMALE
Min age
—
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Not having been diagnosed with breast cancer, * not performing regular self-examinations (those who performed self-examinations at least once a month were excluded), * not having had a mammogram (those who had a mammogram within the first six months after training were excluded), * not having undergone a clinical breast examination (those who underwent a clinical breast examination within the first 6 months after the training were excluded), * not breastfeeding or being pregnant, being literate, owning a smartphone, * having internet access, * not having uterine abnormalities, * having ovaries, * not having used sex hormones. Exclusion Criteria: * never experiencing menopausal symptoms, * undergoing surgical menopause, * currently or previously using hormonal therapy, * having a psychiatric disorder, * having menstruated in the past year, * incomplete forms, * not fully participating in video-based education programs.

Primary outcome measure(s)

  • menopause symptom scale — 3 month
    The scale consists of a total of 11 items and 3 subscales. These 3 subscales are called the "Somatic Complaints subscale," "Psychological Complaints subscale," and "Urogenital Complaints subscale." The scale is a 5-point Likert scale. The score obtained from the scale ranges from 0 to 44 points. An increase in the total score obtained from the scale indicates an increase in the severity of menopausal complaints experienced.

Trial sites (1)

FacilityCityRegionStatus
Inonu University Bartın Bartın
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07042737 on ClinicalTrials.gov ↗ ← All trials in Turkey